158 related articles for article (PubMed ID: 15390081)
1. Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.
Sirotnak FM; She Y; Khokhar NZ; Hayes P; Gerald W; Scher HI
Mol Carcinog; 2004 Nov; 41(3):150-63. PubMed ID: 15390081
[TBL] [Abstract][Full Text] [Related]
2. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
Gregory CW; Hamil KG; Kim D; Hall SH; Pretlow TG; Mohler JL; French FS
Cancer Res; 1998 Dec; 58(24):5718-24. PubMed ID: 9865729
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.
Tepper CG; Boucher DL; Ryan PE; Ma AH; Xia L; Lee LF; Pretlow TG; Kung HJ
Cancer Res; 2002 Nov; 62(22):6606-14. PubMed ID: 12438256
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
[TBL] [Abstract][Full Text] [Related]
7. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.
Thompson VC; Hurtado-Coll A; Turbin D; Fazli L; Lehman ML; Gleave ME; Nelson CC
Prostate; 2010 Jul; 70(10):1134-45. PubMed ID: 20503398
[TBL] [Abstract][Full Text] [Related]
8. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
11. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.
Zou JX; Zhong Z; Shi XB; Tepper CG; deVere White RW; Kung HJ; Chen H
Prostate; 2006 Oct; 66(14):1474-86. PubMed ID: 16921507
[TBL] [Abstract][Full Text] [Related]
12. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
13. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
[TBL] [Abstract][Full Text] [Related]
14. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
15. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Sirotnak FM; She Y; Lee F; Chen J; Scher HI
Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
[TBL] [Abstract][Full Text] [Related]
16. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation.
Kikugawa T; Kinugasa Y; Shiraishi K; Nanba D; Nakashiro K; Tanji N; Yokoyama M; Higashiyama S
Prostate; 2006 Jul; 66(10):1092-9. PubMed ID: 16637071
[TBL] [Abstract][Full Text] [Related]
17. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
Gao J; Arnold JT; Isaacs JT
Cancer Res; 2001 Jul; 61(13):5038-44. PubMed ID: 11431338
[TBL] [Abstract][Full Text] [Related]
18. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer.
Mohler JL; Morris TL; Ford OH; Alvey RF; Sakamoto C; Gregory CW
Prostate; 2002 Jun; 51(4):247-55. PubMed ID: 11987153
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
[TBL] [Abstract][Full Text] [Related]
20. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
